Eva Rossmann

Roche (Switzerland) — Switzerland

Medicine · Health Sciences

14h-index948citations84works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(33), Cancer Immunotherapy and Biomarkers(23), Radiopharmaceutical Chemistry and Applications(23), HER2/EGFR in Cancer Research(21), Immunotherapy and Immune Responses(20)

Publications84 total

Supplementary Figure 6 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors
2026Open Access
Figure S9 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors
2026Open Access
Supplementary Methods 1 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors
2026Open Access
Supplementary Figure 7 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors
2026Open Access
Supplementary Figure 4 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors
2026Open Access
Figure S8 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors
2026Open Access
Supplementary Figure 2 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors
2026Open Access
Supplementary Figure 1 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors
2026Open Access
Supplementary Table 1 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors
2026Open Access
Data from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors
2026Open Access
Supplementary Figure 5 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors
2026Open Access
Supplementary Figure 3 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors
2026Open Access
Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer·2026Open Access
Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors
Clinical Cancer Research·2025Open Access
Supplementary Figure 4 from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
Supplementary Figure 2 from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
Table 1 from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
Table 3 from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
Table 4 from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
Supplementary Figure 1A and 1B from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
page 1 of 5Next →

Frequent Co-authors

Christophe Boetsch(19), Håkan Mellstedt(17), Kristoffer Staal Rohrberg(14), Anders Österborg(13), David Dejardin(10), Valentina Gambardella(10), Michael Ong(10), Jean‐Pascal Machiels(10), Miguel F. Sanmamed(10), Anna Spreafico(10), Daniel J. Renouf(10), Rachel Galot(10), Emiliano Calvo(10), Aung Naing(10), Samira Curdt(10), Tamara Tanos(10), Kevin Smart(10), Maria Amann(10), Yuying Xie(10), Linxinyu Xu(10)